Details

Autor(en) / Beteiligte

• MURPHY, P. S
• VIVIERS, L
• ABSON, C
• ROWLAND, I. J
• BRADA, M
• LEACH, M. O
• DZIK-JURASZ, A. S. K

Titel

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

Ist Teil von

• British journal of cancer, 2004-02, Vol.90 (4), p.781-786

Ort / Verlag

Basingstoke: Nature Publishing Group

Erscheinungsjahr

2004

Quelle

MEDLINE

Beschreibungen/Notizen

• Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy ((1)H-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for low-grade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment. Patients (n=12) received oral temozolomide (200 mg m(-2) day(-1)) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo time)=20 ms) and long (TE=135 ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite profiles. The mean tumour volume change at the end of treatment was -33% (s.d.=20). The dominant metabolite in long echo time spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment (P=0.035) and 3-month scan (P=0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide.